#Chicago #Denmark #Lundbeck #Vyepti #bocunebart

Lundbeck to Showcase New Data at AAN 2026

H. Lundbeck A/S has announced its participation in the 2026 American Academy of Neurology (AAN) Annual Meeting, set to take place in Chicago from April 18 to 22. The meeting will feature seven compelling abstracts highlighting the company's innovations in the treatment of neurology-related conditions. Lundbeck, known for its biology-driven therapies, aims to address significant unmet medical needs in conditions such as migraine, childhood-onset epilepsy, and multiple system atrophy (MSA).

Key Highlights of Lundbeck's Presentations

The presentations will include new findings on the Phase 1 safety and tolerability data for bocunebart (Lu AG09222), a novel investigational anti-PACAP monoclonal antibody aimed at preventing migraines. This groundbreaking treatment diverges from the existing preventive therapies that target the calcitonin gene-related peptide (CGRP) mechanism.

Additionally, data regarding VYEPTI® (eptinezumab), an intravenous anti-CGRP preventive treatment, will also be a focal point. Three distinct abstracts will cover clinical data and real-world evidence on this treatment, demonstrating its efficacy in patients who had previously failed to respond to other preventive methods.

Lundbeck will further present research on bexicaserin, an investigational agent targeting developmental and epileptic encephalopathies (DEEs) like Dravet syndrome and Lennox-Gastaut syndrome. The trial results will delve into the long-term safety and effectiveness of bexicaserin, garnering interest from both clinical practitioners and researchers.

Lundbeck's Vision for Neuroscience

Johan Luthman, EVP and Head of Research & Development at Lundbeck, stated, "Neuroscience is at a critical juncture. Breakthroughs in human genetics, biomarker validation, and a deeper understanding of migraine and neuro-rare diseases are paving the way for promising therapeutic avenues." He emphasized Lundbeck's mission to translate these scientific insights into actionable drug development that prioritizes areas with minimal or no treatment options.

Investigational Highlights:

1. Bocunebart (Lu AG09222)
- Presentation Type: Oral Presentation
- Abstract Focus: Safety and tolerability when co-administered with a gepant in migraine patients.
- Date: April 22, 2026
- Details: Evaluates the compound’s interaction with a class of CGRP receptor antagonists commonly used in migraine management.

2. VYEPTI® (eptinezumab)
- Presentation Type: Poster Presentations
- Abstracts Include:
- Real-world effectiveness in patients with previous treatment failures.
- Cognitive symptom impacts post-treatment.
- Effects on quality of life and headache-free durations.

3. Bexicaserin
- Presentation Type: Poster Presentation
- Abstract Focus: 12-month results from the PACIFIC trial's open-label extension, showcasing its potential as a treatment for complex seizures in DEEs.

Addressing Rare Diseases

Lundbeck’s commitment to addressing rare neurological disorders underscored by their research on MSA will also be showcased. Findings from a Delphi consensus study will provide insights into clinical progression assessment methods in MSA, a condition severely impacting quality of life for patients and caregivers alike. Currently, MSA has no approved treatments aimed at slowing disease progression.

Conclusion

Lundbeck's presence at AAN 2026 signifies a robust commitment to advancing treatment options for neurological diseases, particularly in areas with substantial unmet needs. By focusing on innovative drug development backed by solid research, Lundbeck aims to transform the landscape of treatment for serious brain diseases, ultimately enhancing patient outcomes and quality of life.

For ongoing updates and live presentations, attendees can follow Lundbeck's contributions during the AAN Annual Meeting and engage with their expert teams to learn more about the groundbreaking therapies in development.

For more detailed information about Lundbeck’s latest research and developments, please visit Lundbeck's official website.